[go: up one dir, main page]

AR123730A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR123730A1
AR123730A1 ARP210102801A ARP210102801A AR123730A1 AR 123730 A1 AR123730 A1 AR 123730A1 AR P210102801 A ARP210102801 A AR P210102801A AR P210102801 A ARP210102801 A AR P210102801A AR 123730 A1 AR123730 A1 AR 123730A1
Authority
AR
Argentina
Prior art keywords
compounds
och3
independently selected
tau protein
tau
Prior art date
Application number
ARP210102801A
Other languages
English (en)
Inventor
Sreenivasachary Nampally
Emanuele Gabellieri
P Dreyfus Vronique Dehlinger
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of AR123730A1 publication Critical patent/AR123730A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que se pueden emplear en el tratamiento, alivio o prevención de un grupo de enfermedades, trastornos y/o anomalías asociadas con el plegamiento incorrecto de la proteína Tau y/o agregación patológica de la proteína Tau (unidad asociada a tubulina) que incluye, entre otros, los ovillos neurofibrilares (NFT), tal como la enfermedad de Alzheimer (AD). La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos, métodos que utilizan dichos compuestos, combinaciones que comprenden dichos compuestos, medicamentos que los contienen, y sus usos en enfermedades, trastornos y/o anomalías asociadas con el plegamiento incorrecto de proteína Tau y/o la agregación patológica de proteína Tau (unidad asociada a tubulina). Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, en donde Y es S u O; R¹ es un heterociclilo mono o bicíclico; Q¹ y Q⁴ son diferentes y se seleccionan independientemente de CH y N; Q² y Q³ son diferentes y se seleccionan independientemente de N, C y C-L-R², en donde al menos uno de Q² o Q³ es C-L-R²; L es -NH(CO)-, C₂₋₄alquinilo, -NH-; o L es un heteroarilo; o L es un heterociclilo saturado o insaturado de 5 a 8 miembros opcionalmente sustituido con halo o alquilo C₁₋₄; o L es un enlace; R² se selecciona de los compuestos del grupo de fórmulas (2), en donde R es alquilo C₁₋₄ o H; Z¹ es N, CH, C-F, y C-OCH₃; Z¹’ es N, CH, C-F, C-CH₃, y C-OCH₃; Z² es N, CH, C-F, C-CH₃, y C-OCH₃; Z³ o Z⁴ se seleccionan independientemente de N, CH, C-F y C-CH₃; y en donde cuando Z⁴ es N, al menos uno de Z¹, Z¹’, Z², Z³ es C-F.
ARP210102801A 2020-10-15 2021-10-07 Compuestos novedosos AR123730A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063092105P 2020-10-15 2020-10-15

Publications (1)

Publication Number Publication Date
AR123730A1 true AR123730A1 (es) 2023-01-04

Family

ID=78212109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102801A AR123730A1 (es) 2020-10-15 2021-10-07 Compuestos novedosos

Country Status (8)

Country Link
US (1) US20230391774A1 (es)
EP (1) EP4229052A1 (es)
JP (1) JP2023546094A (es)
CN (1) CN116568684A (es)
AR (1) AR123730A1 (es)
CA (1) CA3195535A1 (es)
TW (1) TWI835009B (es)
WO (1) WO2022078971A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120500485A (zh) 2023-02-14 2025-08-15 深圳众格生物科技有限公司 一种抑制nlrp3的化合物及制备方法和应用
WO2024206127A2 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation Compounds, compositions, and method of inhibiting tau protein and alpha-synuclein aggregation
WO2024220747A2 (en) * 2023-04-20 2024-10-24 Lysoway Therapeutics, Inc. Fluorinated cyclic derivatives of sulfonamides and sulfones, and compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291910B2 (en) 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2006251832A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP2017507983A (ja) * 2014-03-18 2017-03-23 アイティーオス セラペウティクス 新規な３−インドール置換誘導体、医薬組成物、および使用方法
JP2019512491A (ja) * 2016-03-11 2019-05-16 エーシー・イミューン・エス・アー 診断及び療法のための二環式化合物
MX2020007031A (es) * 2018-01-05 2020-12-03 Ac Immune Sa Derivados de 1,3,4,5-tetrahidro -2 h-pirido [4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tales como la enfermedad de alzheimer.
US10633383B2 (en) * 2018-01-05 2020-04-28 Ac Immune Sa Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
TWI743484B (zh) * 2018-06-04 2021-10-21 瑞士商Ａｃ免疫公司 用於治療、改善或預防與tau聚集物相關之病症的新穎化合物
ES2924950T3 (es) * 2018-06-04 2022-10-11 Ac Immune Sa Novedosos compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados Tau
CN113453688A (zh) * 2019-03-01 2021-09-28 Ac免疫有限公司 用于治疗、减轻或预防与Tau聚集体相关的病症的新化合物

Also Published As

Publication number Publication date
CA3195535A1 (en) 2022-04-21
EP4229052A1 (en) 2023-08-23
JP2023546094A (ja) 2023-11-01
TWI835009B (zh) 2024-03-11
CN116568684A (zh) 2023-08-08
US20230391774A1 (en) 2023-12-07
WO2022078971A1 (en) 2022-04-21
TW202231272A (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
AR123730A1 (es) Compuestos novedosos
US12325710B2 (en) Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders
JP6046154B2 (ja) Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
PE20242113A1 (es) Compuestos de quinolina como inhibidores de kras
PE20220140A1 (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
CL2018000036A1 (es) Derivados etinilo
EP2701699A1 (en) Inhibitors of histone deacetylase
BR112014009306B1 (pt) Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
US11345666B2 (en) Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
AR088352A1 (es) Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
AR121744A1 (es) MODULADORES DE a 1-ANTITRIPSINA
JP2016513130A5 (es)
BR112020003245A2 (pt) 3-ciclobuteno-1,2-dionas 3,4-dissubstituído e uso do mesmo
WO2005030188A2 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
AR117835A1 (es) Complejo diastereoisomérico enriquecido de gadolinio y de un ligando quelante a base de pcta, y proceso de preparación y purificación del mismo
WO2019244002A1 (en) Pyridinyl pyrazoles as modulators of roryt
UY39265A (es) Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen
HK1223919A1 (zh) 氟-萘基衍生物
AR104331A1 (es) Derivados de tetrazol
AR121544A1 (es) Inhibidores de la vía de señalización por cbp / catenina y sus usos
AR131263A1 (es) Compuestos de pirrolil-sulfonamida fusionados
PT99862A (pt) Processo para a preparacao de inibidores da protease retroviral derivados de 3-cloro-2-clorometil-1-propeno
AR123170A1 (es) Inhibidores atr y usos de estos
KR20130082453A (ko) 아밀로이드 병리의 치료 및 예방을 위한 플루페녹신 유도체